ClinicalTrials.gg
Status unknownNCT04403100Updated Jan 26, 2021

Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"

A Phase 3 interventional study of Hydroxychloroquine Sulfate Tablets and Lopinavir/ Ritonavir Oral Tablet in COVID-19, Coronavirus Infection and Virus Disease, sponsored by Cardresearch. Status unknown at 4 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.

Sponsored by Cardresearch · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,968
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing hydroxychloroquine in COVID-19 — 3 open to participants now, 3 under way, 2 of them phase 3. Hydroxychloroquine · COVID-19.

Planned enrollment
6th of 125
1,968 · median 105
Started
2020
with 117 others
Phase 3
49 of 125
2 open now
Registered
95th of 125
by date

Among the 125 studies testing hydroxychloroquine in COVID-19, this one is the 6th largest by planned enrollment, is one of 118 that started in 2020, is one of 49 in phase 3, and was the 95th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 125 studies testing hydroxychloroquine in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About hydroxychloroquine

Hydroxychloroquine: first FDA approval 1955 (PLAQUENIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing hydroxychloroquine in COVID-19, or all of them as a file.
02

Study summary

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.

Read the detailed description

In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China. A new subtype of coronavirus has been identified as the causative agent of this condition. On February 11, 43,103 cases had already been described and on this day the World Health Organization (WHO) named this disease as COVID-19. With. The disease had spread out to several countries on different continents and on March 11, WHO declared a state of worldwide pandemic. Today (April 25, 2020) there are 2,719,897 cases and 187,705 deaths documented, with a global case-fatality ratio of 6.9%.

To date, no treatment has been identified as effective in combating this disease which has been identified as with high mortality, therefore there are no specific therapeutic options. So far, efforts have been focused on the treatment of patients hospitalized with dyspnea and, although several promising drugs are being evaluated, none has demonstrated effectiveness in reducing morbidity and mortality at this stage of the disease, suggesting that perhaps the best time to use medications either before the onset of severe symptoms of respiratory distress.

Thus, we propose the use of two drugs which experimentally have shown activity against SARS-CoV2 and being used in severely ill patients with COVID-19. Our hypothesis is that perhaps using such drugs before onset of complications will allow better outcomes on this patient population.

03

Conditions studied

  • COVID-19
  • Coronavirus Infection
  • Virus Disease
  • Acute Respiratory Infection
  • SARS-CoV Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with RT-PCR diagnosis of COVID-19 or a clinical condition compatible with COVID-19 and respiratory symptoms, presenting:

A. Persistent dry cough associated with axillary temperature > 37.7 Celsius;

OR

B. Recent onset of Flu-like Respiratory Symptoms associated with dry cough

OR

C. Tomographic image compatible with COVID 19 infection;

  1. Men and women aged > 50 years OR: Patients over 18 years of age with at least one of the following criteria
  • Diabetes requiring oral medication or insulin.
  • Arterial hypertension requiring at least 01 oral medication for treatment
  • Known cardiovascular diseases (CHF of any etiology, documented Coronary Artery Disease, Clinically overt heart disease)
  • Symptomatic chronic lung disease and/ or medically controlled
  • Patients with a history of transplantation
  • Patient with stage IV chronic kidney disease or on dialysis.
  • Patients on current and/or using therapy (equivalent to at least 10 mg of oral prednisone per day)
  • Willingness to comply with study related procedures

    1. Ability to provide before any protocol-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. RT-PCR exam for COVID-19 negative during the screening visit.
  2. Patients with an acute respiratory condition compatible with COVID-19 being hospitalized;
  3. Patients with an acute respiratory condition and with moderate to high probability of not being a COVID infection 19;
  4. Dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated , acute bronchitis, pneumonia, primary pulmonary arterial hypertension);
  5. Severe respiratory clinical condition, presenting at least ONE of the criteria below:

    1. Respiratory Rate> 28 / min;
    2. Arterial Oxygen Saturation \< 92% with nasal oxygen therapy at 10 l/ min;
    3. PaO2 / FIO2 \<300 mmHg
  1. History of Cardiac Arrhythmia or Long Syndrome; 5. Use of Medications that are known to prolong QTc: Citalopram, Venlafaxine, Bupropion and with no possibility of suspension during the period of medical product administration. 6. Inability to take oral medications; 7. Patients on continuous use of Amiodarone and / or PGE5 Inhibitors (Ex .: Sildenafil and similar). 8. Use of Digoxin, Cyclosporine, Cimetidine, Tamoxifen. 9. Use of anticonvulsants, antifungals, other than corticotherapy. 10. Use of Hydroxychloroquine for other indications 11. Use of chemoprophylaxis for malaria. 12. Psoriasis in a form other than cutaneous 13. Porphyria 14. Use of protease inhibitors, ritonavir or Cobicistat 15. Clinical history of Liver Cirrhosis or C classification; 16. Patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. Patient with a history of hearing loss; 18. Patients with known severe degenerative neurological diseases and / or severe mental illness; 19. Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. Known and / or intolerance to Hydroxychloroquine. 21. Hypersensitivity and / or intolerance Lopinavir / Ritonavir

-

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,968 participants (estimated)

Study arms

  • Active comparator
    Hydroxychloroquine Sulfate

    Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days

    Drug: Hydroxychloroquine Sulfate Tablets

  • Active comparator
    Lopinavir/ Ritonavir

    Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days

    Drug: Lopinavir/ Ritonavir Oral Tablet

  • Active comparator
    Hydroxychloroquine plus Lopinavir/ Ritonavir

    Hydroxychloroquine 400 mg. Loading oral dose of 800 mg followed by orally dose of 400 mg/ day for the following 10 days Plus Lopinavir Ritonavir 200/ 50 mg Loading oral dose of 800/ 200 mg twice a day on day 1 followed by 400/100 mg orally twice a day for the following 9 days

    Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets

  • Placebo comparator
    Placebo

    Placebo Twice a day from day 1 through day 10.

    Drug: Placebo

Interventions

  • DrugHydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days

  • DrugLopinavir/ Ritonavir Oral Tablet

    tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days

  • DrugHydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets

    Drug pages: HydroxychloroquineStudies of HydroxychloroquineHydroxychloroquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LopinavirStudies of LopinavirLopinavir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RitonavirStudies of RitonavirRitonavir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days plus Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days

  • DrugPlacebo

    Placebo tablets - 01 tablet twice daily from day 01 through day 10.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who were hospitalized for progression of COVID-19 disease

    Hospitalization is defined as at least 24 hours of acute care in a hospital or similar acute care facility (emergency settings, temporary emergency facilities created for acute care of COVID-19 pandemic)

    Time frame: Measuring during 28-day period since randomization (Intention to treat analysis)

  2. Proportion of participants who died due to COVID-19 progression and/ or complications

    Time frame: Measuring during 28-day period since randomization (Intention to treat analysis)

Secondary outcomes

  1. Proportion of participants with viral load change on 03, 07, 10 and 14 after randomization

    Viral load change on 03, 07, 10 and 14 after randomization (200 patients per arm)

    Time frame: Measuring during 14-day period since randomization

  2. Time to clinical improvement

    Proportion of participants with clinical improvement, defined as normalization of temperature, Respiratory rate, SaO2, and cough relief (\> 50% compared to baseline measured on a visual analog scale) in the last 72 hours.

    Time frame: Measuring during 28-day period since randomization

  3. Time to clinical failure

    Proportion of participants with clinical improvement, defined as as time to need for hospitalization due to dyspnea, death, need for mechanical ventilation, shock and need for vasoactive amines;

    Time frame: Measuring during 28-day period since randomization

  4. Hospitalization for any cause

    Proportion of participants with hospitalization for any cause

    Time frame: Measuring during 28-day period since randomization

  5. Proportion of participants who died due to pulmonary complications

    Time frame: Measuring during 28-day period since randomization

  6. Proportion of participants who died due to cardiovascular complications

    Time frame: Measuring during 28-day period since randomization

  7. Proportion of participants who presented with adverse events

    Evaluation of adverse events evaluated as associated to any of study arms

    Time frame: Measuring during 28-day period since randomization

  8. Time to improvement on respiratory scale symptoms

    Proportion of participants who presented sustained improvement on respiratory scale defined as at least 48 hours of improvement.

    Time frame: Measuring during 28-day period since randomization

  9. proportion of non-adherent participants to any of study drugs

    Time frame: Measuring during 10-day period since randomization

07

Study locations

2 of 4 sites recruiting
  • CARDRESEARCH - Cardiologia Assistencial e de Pesquisa
    Belo Horizonte, Minas Gerais 30150240, Brazil
    Recruiting
  • Pontificia Universidade Catolica de Minas Gerais
    Belo Horizonte, Minas Gerais 30535901, Brazil
    Not yet recruiting
  • Fundo Municipal de Saúde de Betim
    Betim, Minas Gerais 32600412, Brazil
    Recruiting
    • Daniela Silva, MD, PhD · Contactdaninhamed@yahoo.com.br · 5531984923130
    • Daniela Silva, MD, PhD · Principal investigator
  • Universidade Federal de Ouro Preto
    Ouro Preto, Minas Gerais 35400000, Brazil
    Not yet recruiting
    • Leonardo Savassi, MD, PhD · Contactleosavassi@gmail.com
    • Leonardo Savassi, MD, PhD · Principal investigator
08

References and documents

Publications

  • Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, Forrest JI, Harari O, Quirino Dos Santos CV, Guimaraes de Almeida APF, Figueiredo Neto AD, Savassi LCM, Milagres AC, Teixeira MM, Simplicio MIC, Ribeiro LB, Oliveira R, Mills EJ; TOGETHER Investigators. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. JAMA Netw Open. 2021 Apr 1;4(4):e216468. doi: 10.1001/jamanetworkopen.2021.6468. Erratum In: JAMA Netw Open. 2021 Sep 1;4(9):e2130442. doi: 10.1001/jamanetworkopen.2021.30442. PubMed 33885775 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Feb 2021, 7 months after the start.

Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 7 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2020
First posted
May 27, 2020
StartActual
Jun 3, 2020
Primary completionEst.
Feb 1, 2021
CompletionEst.
Feb 1, 2021
Last update
Jan 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04403100
Lead sponsor
Cardresearch
Collaborators
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA, Cytel Inc.
Responsible party
Gilmar Reis (Director - Outpatient Research Clinic, Cardresearch) — Principal investigator
First posted
May 27, 2020
Start date
Jun 3, 2020
Primary completion
Feb 1, 2021 (estimated)
Completion
Feb 1, 2021 (estimated)
Last update
Jan 26, 2021

Study contacts

Gilmar Reis, MD, PhD
Contact
greisbh@uol.com.br
+5531332416574
Rosemary Oliveira, SC
Contact
roliveira@cardresearch.org
+5531992636703
Gilmar Reis, MD, PhD
principal investigator · Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydroxychloroquine · Lopinavir · Ritonavir

Start the discussion